{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:35:47Z","timestamp":1773930947518,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s12020-017-1276-7","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T02:11:29Z","timestamp":1489716689000},"page":"454-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing\u2019s disease"],"prefix":"10.1007","volume":"59","author":[{"given":"Valentina","family":"Guarnotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Ciresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pitrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pizzolanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stella, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93, 2454\u20132462 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1276_CR2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1530\/EJE-12-0921","volume":"168","author":"KI Alexandraki","year":"2013","unstructured":"K.I. Alexandraki, G.A. Kaltsas, A.M. Isidori, H.L. Storr, F. Afshar, I. Sabin, S.A. Akker, S.L. Chew, W.M. Drake, J.P. Monson, G.M. Besser, A.B. Grossman, Long-term remission and recurrence rates in Cushing\u2019s disease: predictive factors in a single-centre study. Eur. J. Endocrinol. 168, 639\u2013648 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"1276_CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1227\/NEU.0b013e31827b966a","volume":"72","author":"RM Starke","year":"2013","unstructured":"R.M. Starke, D.L. Reames, C.J. Chen, E.R. Laws, J.A. Jane Jr., Endoscopic transsphenoidal surgery for Cushing disease: techniques, outcomes, and predictors of remission. Neurosurgery 72, 240\u2013247 (2013)","journal-title":"Neurosurgery"},{"key":"1276_CR4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807\u20132831 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1276_CR5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing\u2019s disease. Endocr. Rev. 36, 385\u2013486 (2015)","journal-title":"Endocr. Rev."},{"key":"1276_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94, 115\u2013122 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1276_CR7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 study group. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366, 914\u2013924 (2012)","journal-title":"N. Engl. J. Med."},{"key":"1276_CR8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"R. Pivonello, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, A. Trovato, G. Hughes, L.R. Salgado, A. Lacroix, J. Schopohl, B.M. Biller, Pasireotide B2305 study group. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a phase III study. Clin. Endocrinol. (Oxf). 81, 408\u2013417 (2014)","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"1276_CR9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"J. Schopohl, F. Gu, R. Rubens, L. Van Gaal, J. Bertherat, M. Ligueros-Saylan, A. Trovato, G. Hughes, L.R. Salgado, M. Boscaro, R. Pivonello, Pasireotide B2305 Study Group. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18, 604\u2013612 (2015)","journal-title":"Pituitary"},{"key":"1276_CR10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28, 412\u2013419 (1985)","journal-title":"Diabetologia"},{"key":"1276_CR11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"M. Matsuda, R. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycaemic insulin clamp. Diabetes Care 22, 1462\u20131470 (1999)","journal-title":"Diabetes Care"},{"key":"1276_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2337\/dc08-1478","volume":"32","author":"KM Utzschneider","year":"2009","unstructured":"K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335\u2013341 (2009)","journal-title":"Diabetes Care"},{"key":"1276_CR13","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycaemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446\u20133453 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1276_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-13-0754","volume":"170","author":"C Giordano","year":"2013","unstructured":"C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing\u2019s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170, 311\u2013319 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"1276_CR15","first-page":"1","volume":"10","author":"V Guarnotta","year":"2016","unstructured":"V. Guarnotta, M.C. Amato, R. Pivonello, G. Arnaldi, A. Ciresi, L. Trementino, R. Citarrella, D. Iacuaniello, G. Michetti, C. Simeoli, A. Colao, C. Giordano, The degree of urinary hypercortisolism is not correlated with the severity of cushing\u2019s syndrome. Endocrine 10, 1\u20139 (2016)","journal-title":"Endocrine"},{"key":"1276_CR16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/15701611113119990125","volume":"12","author":"PP Toth","year":"2014","unstructured":"P.P. Toth, Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr. Vasc. Pharmacol. 12, 653\u2013657 (2014)","journal-title":"Curr. Vasc. Pharmacol."},{"key":"1276_CR17","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1210\/jc.2009-0290","volume":"94","author":"B Zaane Van","year":"2009","unstructured":"B. Van Zaane, E. Nur, A. Squizzato, O.M. Dekkers, M.T. Twickler, E. Fliers, V.E. Gerdes, H.R. B\u00fcller, D.P. Brandjes, Hypercoagulable state in Cushing\u2019s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 94, 2743\u20132750 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1276_CR18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","volume":"97","author":"R Pas van der","year":"2012","unstructured":"R. van der Pas, C. de Bruin, F.W. Leebeek, M.P. de Maat, D.C. Rijken, A.M. Pereira, J.A. Romijn, R.T. Netea-Maier, A.R. Hermus, P.M. Zelissen, F.H. de Jong, A.J. van der Lely, W.W. de Herder, S.W. Lamberts, L.J. Hofland, R.A. Feelders, The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J. Clin. Endocrinol. Metab. 97, 1303\u20131310 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1276_CR19","first-page":"537","volume":"36","author":"MC Amato","year":"2013","unstructured":"M.C. Amato, V. Guarnotta, C. Giordano, Body composition assessment for the definition of cardiometabolic risk. J. Endocrinol. Invest. 36, 537\u2013543 (2013)","journal-title":"J. Endocrinol. Invest."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1276-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T10:30:49Z","timestamp":1517394649000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1276-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1276-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}